TY - T1的量化脑变性肌萎缩性脊髓侧索硬化症使用纹理分析的多通道磁共振成像(4560)JF -神经学乔-神经学六世- 94 - 15补充SP - 4560 AU - Ekhlas Assaedi AU - Pedram Parnianpour AU -安德鲁·吴盟穆首页罕默德汗AU -安妮迪翁盟安吉拉其全称AU -劳伦斯Korngut盟Lorne Zinman盟桑杰卡尔拉Y1 - 2020/04/14 UR - //www.ez-admanager.com/content/94/15_Supplement/4560.abstract N2 -目的:我们的目的是评估脑变性在肌萎缩性脊髓侧索硬化症(ALS)在不同地区的利益(ROI)在T1, t2加权,fluid-attenuated反转恢复(天赋)磁共振成像(MRI)使用ROI-based纹理分析。我们进一步测试结构变化是否与临床特征。背景:常规结构的MRI诊断ALS起有限的作用。纹理分析是一种先进的图像分析方法量化立体像素强度相互关系来检测信息是人类的眼睛听不清。对不同的磁共振成像模式的比较性能检测ALS纹理变化。设计/方法:多通道从49 ALS患者获得的核磁共振图像(59.1±10.1年),51名健康对照组(58.2±10.4岁)在3特斯拉。纹理特征计算的中央前回,皮质脊髓束,和内囊后,使用ANCOVA组间比较。纹理特征被测试的clssification与肌萎缩性侧索硬化症临床能力和相关措施。结果:纹理特征自相关并没有透露患者和健康对照组之间的显著差异。其他纹理特征进行了探讨和逆差异显著不同的患者与健康对照组之间在两国中央前回(术中,0.005),左侧皮质脊髓束(术中,0.05),并对皮质脊髓束(术中;0.005)T1和天赋。 Texture changes, as revealed by inverse difference moment on T1 and FLAIR, in bilateral precentral gyri correlated with finger tapping scores (a measure of upper motor neuron function). A receiver operating characteristic curve analysis using inverse difference moment in left precentral gyrus on T1 yielded an area under the curve of 0.723 (95% confidence interval=0.625 to 0.808, sensitivity 69.39% and specificity 80.39%).Conclusions: Texture analysis on T1-weighted and FLAIR MRI can potentially identify changes consistent with degeneration in the precentral gyri and corticospinal tracts in patients with ALS.Disclosure: Dr. Assaedi has nothing to disclose. Dr. Parnianpour has nothing to disclose. Dr. Wu has nothing to disclose. Dr. Khan has nothing to disclose. Dr. Dionne has nothing to disclose. Dr. Genge has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AB Sciences, AL-S Pharma, Avexis, Biogen, Cytokinetics, MTPA, and Roche. Dr. Genge has received research support from Sanofi-Genzyme. Dr. Korngut has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Novartis, Mitsubishi Tanabe Pharma, Sarepta, Biogen, CSL Behring. Dr. Korngut has received compensation for serving on the Board of Directors of Dataffinity Health. Dr. Korngut holds stock and/or stock options in Dataffinity Health. Dr. Korngut has received research support from Biogen Idec, Sanofi Genzyme, Cytokinetics. Dr. Zinman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Mitsubishi Tanabe Pharma Canada.Dr. Kalra has nothing to disclose. ER -